New pill could help ITP patients who failed standard treatments
NCT ID NCT07294365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an experimental oral drug called DZD8586 (Birelentinib) in adults with primary immune thrombocytopenia (ITP) whose condition did not improve after at least one standard therapy. About 60 participants will receive one of three dose levels to see if it safely raises platelet counts. The study aims to find a new treatment option for people with persistent or chronic ITP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DZD8586 (Birelentinib)
What this could lead to
If it works, this could offer a new oral treatment option for people with ITP who have not responded to standard therapies.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve platelet counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••